FDA Inspection 1326100 — Symbiosis Gesellschaft zur Entwicklung biotechnologischer Produkte und Pharmaka und deren Vertrieb mbH
The FDA completed an inspection of Symbiosis Gesellschaft zur Entwicklung biotechnologischer Produkte und Pharmaka und deren Vertrieb mbH on November 21, 2023 in Eppelheim. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- November 21, 2023
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Eppelheim (Germany)
Additional Details
Mutual Recognition Agreement (MRA)